RWRia Woo

Ria Woo

*This is an algorithmically generated author record based on publicly available information.

Ria Woo has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of an experimental human blood-stage model for studying Plasmodium knowlesi

    by Jeremy S E Gower, Rebecca Webster, Jacob A F Westaway, Jacob A Tickner, Claire Y T Wang, Jenny M Peters, Dean Andrew, Angelica F Tan, Lachlan Webb, Adam J Potter, et al.

    Background: The zoonotic parasite Plasmodium knowlesi is an increasing cause of human malaria in Southeast Asia. We aimed to develop a P. knowlesi induced blood-stage malaria (IBSM) model to facilitate study of parasite biology, host responses to infection, and activity of antimalarial treatments. Methods: We manufactured and characterised a P. knowlesi parasite bank using the P. knowlesi YH1 strain adapted to grow in human serum. This P. knowlesi bank was evaluated in an IBSM study involving four adults intravenously inoculated with P. knowlesi-infected erythrocytes using a dose escalation strategy (10-fold increases from ∼2,800 parasites). Parasitaemia was monitored by qPCR. All participants received curative treatment with artemether-lumefantrine. Endpoints included safety and infectivity of the P. knowlesi bank. Results: Two of the four participants developed detectable parasitaemia. Participant two (administered ∼28,000 parasites) had detectable parasites (∼6 parasites/mL) immediately prior to protocol-defined treatment on day 21. Participant three (administered ∼280,000 parasites) developed detectable parasites on day 17, peaking at 202 parasites/mL just after protocol-defined treatment on day 24; the parasite multiplication rate over 32 hours (PMR32) was 2.33 (95% CI 1.66-3.25). Participant four (also administered ∼280,000 parasites) did not become infected. Adverse events were mostly mild and unrelated to the challenge agent. Conclusions: A GMP-grade P. knowlesi YH1-HS parasite bank was successfully manufactured and shown to establish patent infection in humans. The finding that only one of two participants became infected at the highest inoculum dose highlights the potential for this IBSM model to evaluate factors influencing inter-individual variability in susceptibility to infection.

  • Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum

    by Rebecca Webster, Damian A. Oyong, Stacey Llewellyn, Azrin N. Abd-Rahman, Adam J. Potter, Reena Mukhiya, Nischal Sahai, Indika Leelasena, Eniko Ujvary, Sue Mathison, et al.

    Inhibiting the inflammatory response to malaria offers a promising strategy to improve clinical outcomes and overcome immunoregulatory barriers that hinder development of antiparasitic immunity. We conducted a double-blind, randomized, placebo-controlled trial assessing whether ruxolitinib, a Janus-activated kinase (JAK) 1/2 inhibitor, can reduce inflammatory responses and enhance antiparasitic immunity in malaria-naïve volunteers inoculated with blood-stage Plasmodium falciparum . Twenty participants were inoculated and, on day 8, randomized to receive artemether-lumefantrine with either ruxolitinib or placebo. Ninety days later, participants underwent a second inoculation. Ruxolitinib was safe and well tolerated; moreover, it attenuated inflammatory responses to the initial infection, with reduced posttreatment increases in C-reactive protein and markers of disease severity, including angiopoietin-2 and intercellular adhesion molecule-1. Ruxolitinib also enhanced immune memory after the second infection, with elevated human leukocyte antigen–DRA and 4-1BB, consistent with increased T cell activation. These data support the further evaluation of ruxolitinib as an adjunctive treatment to improve clinical outcomes and boost antiparasitic immunity in clinical malaria.